STEVENSON, Md., Sept. 25, 2017 -- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of Florida on behalf of purchasers of PetMed Express, Inc. (Nasdaq:PETS) (“PetMed” or the “Company”) securities during the period between May 8, 2017 and August 23, 2017, inclusive (the “Class Period”). Investors who wish to become proactively involved in the litigation have until October 24, 2017 to seek appointment as lead plaintiff.
If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in PetMed securities during the Class Period. Members of the class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No class has yet been certified in the above action.
The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the defendants’ failure to disclose during the Class Period that the Company was marketing dangerous and addictive animal drugs to humans, was vulnerable to potential civil and criminal liability, and could be halted from advertising by Google.
According to the complaint, following an August 23, 2017 research report alleging that the Company was aggressively marketing dangerous painkillers to human opiate and drug users, which could capture the attention of regulators, the value of PetMed shares declined significantly.
If you have suffered a loss in excess of $100,000 from investment in PetMed securities purchased on or after May 8, 2017 and held through the revelation of negative information during and/or at the end of the Class Period and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, without cost or obligation to you, please visit our website at http://www.browerpiven.com/currentsecuritiescases.html. You may also request more information by contacting Brower Piven either by email at [email protected] or by telephone at (410) 415-6616.
Attorneys at Brower Piven have extensive experience in litigating securities and other class action cases and have been advocating for the rights of shareholders since the 1980s. If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice. You need take no action at this time to be a member of the class.
CONTACT: Charles J. Piven
Brower Piven, A Professional Corporation
1925 Old Valley Road
Stevenson, Maryland 21153
Telephone: 410-415-6616
[email protected]


Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Samsung Electronics Shares Jump on HBM4 Mass Production Report
Anta Sports Expands Global Footprint With Strategic Puma Stake
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 



